An interventional study of Conservative treatment by casting and surgical treatment via percutaneous pinning UGA in Humeral Fractures, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Year to 12 Years. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary aim of this research is to compare the efficacy of conservative treatment versus surgical treatment for Gartland type II supracondylar humerus fractures in children. The comparison focuses on assessing differences in clinical outcomes functional recovery times, and complication rates between the two treatment groups.
Supracondylar Humerus Fractures are the most common type of elbow fracture in children, typically occurring between the ages of five and seven. These injuries are critical due to their proximity to major neurovascular structures, making prompt and appropriate management essential to prevent severe complications. The vast majority (approximately 98%) of SCHFs are extension-type injuries, resulting from a fall onto an outstretched hand with the elbow hyperextended.
Classification: The Gartland System The classification is based on the degree of displacement of the distal fragment relative to the proximal fragment, as seen on a lateral radiograph.
Type I stable, nondisplaced fractures are managed non-operatively.
Type III and IV are highly unstable fractures that require urgent intervention to achieve and maintain reduction .
Treatment: Closed Reduction and Percutaneous Pinning (CRPP) is the mainstay of treatment .Open reduction may be necessary if closed reduction fails or if there is a vascular compromise requiring exploration.
•Goal: Anatomical reduction and stable fixation to prevent malunion and neurovascular complications.
106 studies on the registry are indexed under Humeral Fractures; 20 are open to participants now.
This study's planned enrollment of 50 is below the median of 56 across 64 interventional studies indexed under Humeral Fractures.
Browse Humeral Fractures studies →Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children with Gartland type II supracondylar humeral fractures will be treated conservatively using closed reduction followed by immobilization in an above-elbow cast . Patients will be followed up clinically and radiologically at regular intervals to assess fracture alignment, healing, and functional outcomes.
Other: Conservative treatment by casting
Children will undergo surgical treatment via Closed reduction and percutaneous pinning under general anesthesia. Postoperative follow-up will include clinical and radiological assessment of fracture healing, alignment, and complications.
Procedure: surgical treatment via percutaneous pinning UGA
Closed reduction of Gartland type II supracondylar humeral fracture under appropriate analgesia or anesthesia, followed by immobilization using an above-elbow cast. Patients will undergo regular clinical and radiographic follow-up to monitor fracture alignment, healing, and functional recovery.
surgical treatment vis Closed reduction and percutaneous pinning under general anesthesia. Postoperative care includes clinical and radiographic follow-up to assess fracture healing, alignment, and potential complications.
Functional outcome assessed by Modified Disabilities of the Arm, Shoulder and Hand (QuickDASH) score
Functional outcome will be evaluated using the Modified QuickDASH questionnaire. Scores range from 0 to 100, with higher scores indicating greater disability.
Time frame: 1 year
Elbow flexion range of motion (degrees)
Measured in degrees using a goniometer to assess maximum elbow flexion.
Time frame: 1 month, 3 months, and 6 months post-intervention
Elbow extension range of motion (degrees)
Measured in degrees using a goniometer to assess maximum elbow extension.
Time frame: 1 month, 3 months, and 6 months post-intervention
Pain assessed using Visual Analog Scale (VAS)
Pain is measured on a scale from 0 to 10, where 0 indicates no pain and 10 indicates worst possible pain.
Time frame: 1 month, 3 months, and 6 months post-intervention
Baumann angle (degrees)
Measured on standard anteroposterior elbow radiographs to assess coronal alignment.
Time frame: Immediately post-reduction and at 6 months
Anterior humeral line alignment (normal/abnormal)
Assessed on lateral elbow radiographs to evaluate sagittal alignment.
Time frame: Immediately post-reduction and at 6 months
Loss of reduction (yes/no)
Defined as displacement of fracture fragments on follow-up radiographs.
Time frame: Up to 6 months post-intervention
Incidence of nerve injury (yes/no)
Includes any documented motor or sensory nerve deficit following treatment.
Time frame: Up to 6 months post-intervention
Incidence of infection (yes/no)
Includes superficial or deep infection related to treatment.
Time frame: Up to 6 months post-intervention
No study locations are listed for this record.
Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.
Of 26 interventional studies with no phase under Humeral Fractures, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.